Submit

Login Login

Register Register

Home / Journals / OR / Special Issue / Advances in Cancer Immunotherapy
Journal Menu
Special Issues
Table of Content

All issues

Online First

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

Past Issues

Advances in Cancer Immunotherapy

Submission Deadline: 31 March 2025 (closed) View: 359 Submit to Special Issue

Guest Editors

Zongsheng Guo, Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, UNITED STATES. E-mail: Zongsheng.Guo@RoswellPark.org

Wenxue Ma, Department of Medicine, Sanford Stem Cell Institute and Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA. wma@health.ucsd.edu

Summary

Cancer immunotherapy plays an important role in the treatment of cancer, leveraging the body's own immune system to identify and eradicate malignant cells. This revolutionary approach has shown remarkable success in various cancer types, offering new hope to patients worldwide.

 

This Special Issue focuses on the latest advancements in cancer immunotherapy, a rapidly evolving field that harnesses the body’s immune system to combat cancer. We invite researchers to submit original research articles, comprehensive reviews, and insightful case studies that explore innovative immunotherapeutic approaches, including immune checkpoint inhibitors, CAR T-cell therapy, cancer vaccines, and novel biomarkers. Contributions that address mechanisms of resistance, combination therapies, and translational research bridging laboratory findings to clinical applications are particularly encouraged. Our goal is to compile a diverse collection of pioneering studies that will drive forward the understanding and effectiveness of immunotherapy in oncology. Join us in advancing the fight against cancer through the power of the immune system.

Keywords

1. Cancer immunotherapy
2. Immune checkpoint inhibitors
3. CAR T-cell therapy
4. Cancer vaccines
5. Novel biomarkers

Published Papers

Show export options

  • Open Access

    REVIEW

    The effect of concomitant drugs on oncological outcomes in patients treated with immunotherapy for metastatic urothelial carcinoma: a narrative review

    MICHELE MAFFEZZOLI, GIULIA CLAIRE GIUDICE, GIACOMO IOVANE, MARTINA MANINI, ELENA RAPACCHI, GIUSEPPE CARUSO, NICOLA SIMONI, STEFANIA FERRETTI, STEFANO PULIATTI, DAVIDE CAMPOBASSO, SEBASTIANO BUTI
    Oncology Research, Vol.33, No.4, pp. 741-757, 2025, DOI:10.32604/or.2024.057278
    （This article belongs to the Special Issue: Advances in Cancer Immunotherapy)
    Abstract Background: immune checkpoint inhibitors (ICIs) have revolutionized the treatment of metastatic urothelial carcinoma (mUC), significantly improving survival outcomes. However, a subset of patients do not respond to ICIs, prompting research into potential predictive factors. Commonly prescribed medications such as corticosteroids, proton-pump inhibitors (PPIs), antibiotics (Abs), antihypertensives, and analgesics may influence ICI effectiveness. Methods: we conducted a literature search on PubMed to investigate the impact of concomitant medications on the outcomes of patients with mUC, treated with ICIs. We selected the most relevant studies and performed a narrative review. Results: corticosteroids, PPIs and Abs have been associated More >

    View

    698

    Download

    208

  • Open Access

    ARTICLE

    Exploring the therapeutic potential of precision T-Cell Receptors (TCRs) in targeting KRAS G12D cancer through in vitro development

    WEITAO ZHENG, DONG JIANG, SONGEN CHEN, MEILING WU, BAOQI YAN, JIAHUI ZHAI, YUNQIANG SHI, BIN XIE, XINGWANG XIE, KANGHONG HU, WENXUE MA
    Oncology Research, Vol.32, No.12, pp. 1837-1850, 2024, DOI:10.32604/or.2024.056565
    （This article belongs to the Special Issue: Advances in Cancer Immunotherapy)
    Abstract Objectives: The Kirsten rat sarcoma virus (KRAS) G12D oncogenic mutation poses a significant challenge in treating solid tumors due to the lack of specific and effective therapeutic interventions. This study aims to explore innovative approaches in T cell receptor (TCR) engineering and characterization to target the KRAS G12D7-16 mutation, providing potential strategies for overcoming this therapeutic challenge. Methods: In this innovative study, we engineered and characterized two T cell receptors (TCRs), KDA11-01 and KDA11-02 with high affinity for the KRAS G12D7-16 mutation. These TCRs were isolated from tumor-infiltrating lymphocytes (TILs) derived from tumor tissues of patients More >

    View

    1158

    Download

    274

  • Open Access

    REVIEW

    mRNA vaccines: a new era in vaccine development

    SHUBHRA CHANDRA, JENNIFER C. WILSON, DAVID GOOD, MING Q. WEI
    Oncology Research, Vol.32, No.10, pp. 1543-1564, 2024, DOI:10.32604/or.2024.043987
    （This article belongs to the Special Issue: Advances in Cancer Immunotherapy)
    Abstract The advent of RNA therapy, particularly through the development of mRNA cancer vaccines, has ushered in a new era in the field of oncology. This article provides a concise overview of the key principles, recent advancements, and potential implications of mRNA cancer vaccines as a groundbreaking modality in cancer treatment. mRNA cancer vaccines represent a revolutionary approach to combatting cancer by leveraging the body’s innate immune system. These vaccines are designed to deliver specific mRNA sequences encoding cancer-associated antigens, prompting the immune system to recognize and mount a targeted response against malignant cells. This personalized… More >

    Graphic Abstract

    mRNA vaccines: a new era in vaccine development

    View

    2141

    Download

    698

Share Link